Literature DB >> 19806609

Cost-utility of treatment of bulimia nervosa.

Veera Pohjolainen1, Pirjo Räsänen, Risto P Roine, Harri Sintonen, Kristian Wahlbeck, Hasse Karlsson.   

Abstract

OBJECTIVE: The costs of treating eating disorders are high. Our objective was to perform a cost-utility analysis of treatment of bulimia nervosa.
METHOD: 72 patients entering treatment of bulimia nervosa (ICD-10 diagnosis) completed the 15D health-related quality of life (HRQoL) questionnaire and the Eating Disorder Inventory (EDI) before and 6 months after the start of treatment. Quality-adjusted life years (QALYs) gained were calculated and cost-utility was assessed within the time horizon of 10 years.
RESULTS: Baseline HRQoL was severely impaired in the patients. As a consequence of treatment, mean HRQoL improved clinically and statistically significantly. The cost per QALY gained varied from €1,455 to €16,481 (from €4,428 to €19,663 discounted at 5%) depending on the assumptions used in the analysis. DISCUSSION: HRQoL of bulimia nervosa patients is severely impaired, but treatment has a clear positive effect on HRQoL. The cost per QALY gained is comparable to many other treatments.
© 2009 by Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19806609     DOI: 10.1002/eat.20754

Source DB:  PubMed          Journal:  Int J Eat Disord        ISSN: 0276-3478            Impact factor:   4.861


  9 in total

1.  The cost-effectiveness of school-based eating disorder screening.

Authors:  Davene R Wright; S Bryn Austin; H LeAnn Noh; Yushan Jiang; Kendrin R Sonneville
Journal:  Am J Public Health       Date:  2014-07-17       Impact factor: 9.308

2.  Cost-effectiveness of achieving clinical improvement with a dissonance-based eating disorder prevention program.

Authors:  Laura Akers; Paul Rohde; Eric Stice; Meghan L Butryn; Heather Shaw
Journal:  Eat Disord       Date:  2017-03-13       Impact factor: 3.222

3.  Health-related quality of life of head and neck cancer patients with successful oncological treatment.

Authors:  V Loimu; A A Mäkitie; L J Bäck; H Sintonen; P Räsänen; R Roine; K Saarilahti
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-07-02       Impact factor: 2.503

4.  Long-term health-related quality of life in eating disorders.

Authors:  Veera Pohjolainen; Salla Koponen; Pirjo Räsänen; Risto P Roine; Harri Sintonen; Hasse Karlsson
Journal:  Qual Life Res       Date:  2016-02-20       Impact factor: 4.147

Review 5.  The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.

Authors:  Michael Sonntag; Hans-Helmut König; Alexander Konnopka
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

6.  Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.

Authors:  Malek B Hannouf; Chander Sehgal; Jeffrey Q Cao; Joseph D Mocanu; Eric Winquist; Gregory S Zaric
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

7.  Depression Partially Mediates the Association Between Binge Eating Disorder and Health-Related Quality of Life.

Authors:  Christopher Singleton; Therese E Kenny; Darcy Hallett; Jacqueline C Carter
Journal:  Front Psychol       Date:  2019-02-26

8.  Resistance to treatment and change in anorexia nervosa [corrected]: a clinical overview.

Authors:  Giovanni Abbate-Daga; Federico Amianto; Nadia Delsedime; Carlotta De-Bacco; Secondo Fassino
Journal:  BMC Psychiatry       Date:  2013-11-07       Impact factor: 3.630

Review 9.  A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder.

Authors:  Tamás Ágh; Gábor Kovács; Dylan Supina; Manjiri Pawaskar; Barry K Herman; Zoltán Vokó; David V Sheehan
Journal:  Eat Weight Disord       Date:  2016-03-04       Impact factor: 4.652

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.